LJI and Synbal, Inc. partner to develop better COVID-19 models
New mouse models may shed light on the puzzling aspects of SARS-CoV-2 infection
New mouse models may shed light on the puzzling aspects of SARS-CoV-2 infection
New LJI review shows how T cells target more than 1,400 sites on SARS-CoV-2
Erica Ollman Saphire brings together scientific competitors to find new antibody therapeutics for COVID-19.
Men and women have different immune systems. With a better understanding of sex-specific immune differences, scientists can more effectively fight infections, cancers, heart disease, and even pregnancy complications.
San Diego biotech entrepreneurs François Ferré, Ph.D., and Magda Marquet, Ph.D., knew supporting LJI would be critical for advancing our understanding of COVID-19.
The bioinformatics tools Dr. Peters has developed are invaluable for immunologists worldwide.
Reactions reflect unique features of an individual’s immune system, not the strength of a response
Antibodies can change to counter new forms of the shape-shifting virus, research hints
LA JOLLA—A team of scientists at La Jolla Institute for Immunology (LJI) has won the XPRIZE Rapid COVID Testing competition.
In addition to developing the antibodies for use in diagnostic applications based on N protein-specific antibodies, Leinco will make these antibodies commercially available as part of their extensive catalogue of research tools.